![]() ![]() primarily due to sales of our LogixSmart COVID-19 test throughout the world, which was developed in response to the current COVID-19 pandemic. Its revenues for 2018 totaled $74 million presented a truly epic growth. White Diamond Research hit it hard with its 03/2020 article, "There Doesn't Appear To Be Any Real Interest In Co-Diagnostics' Coronavirus Test - We Reiterate Our $1 Price Target".Īs revealed by its 10-K for 2020 filed, Co-Diagnostics was just beginning its commercial journey when the pandemic thrust it forward on the big stage. It had lots to prove as addressed by the three aforementioned bearish Co-Diagnostics' articles on Seeking Alpha. On its hired IR firm was already out with a release touting its "completed initial design work on an accurate diagnostic test to detect the new strain of coronavirus, differentiating it from other similar viruses."Īt this point Co-Diagnostics was talking big. For Co-Diagnostics it was like finding gold on the street as reflected by it price chart below:Įven before the pandemic was well recognized, Co-Diagnostics was brilliantly alert to the potential presented by the "the deadly, rapidly spreading new coronavirus". The pandemic hit the world with stark force on when WHO declared COVID-19 a Pandemic. When you move beyond positive ratings and kick the tires the situation is more nuanced In the next section I will review some of the bears' arguments as applied to Co-Diagnostics. Two of them are by White Diamond Research whom I consider a perma-bear. These three article are from early 2019 and early 2020. ![]() When you go in Seeking Alpha's Co-Diagnostics' ratings way-back machine, the last trio of articles register "strong sells". Seeking Alpha's older library of Co-Diagnostics articles includes ten articles, the most recent seven include three "holds", three "buys" and the most recent 08/2021 article clocks in with a "strong buy". There is no current coverage as I write on. Seeking Alpha authors have not provided extensive coverage for Co-Diagnostics. Its Wall Street Analysts ratings have held solid for three years. Its quant ratings have held steady for over a year since my first article. These positive ratings are not something rare for Co-Diagnostics. Adding to its ratings allure, it receives solid rating from the four Wall Street analysts covering the stock as shown by the analysts ratings tab. Not only does Co-Diagnostics score a rare quant system triple "A+", it also scores "A's" for momentum and revisions. Top scoring stocks in Seeking Alpha's quant universe In using its advanced filter feature on 01/22/22 as I write this article, I find only a handful of stocks in the quant universe of ~600 stocks that scored "A+" for value growth and profitability as shown below: Seeking Alpha's three ratings grades for "growth", "value" and "profitability" seldom speak with unanimity, particularly on the extremes. Co-Diagnostics impresses all three of Seeking Alpha's key ratings metrics I present a sanguine fundamental analysis of its current prospects in today's challenging environment for diagnostics companies. ![]() In this article, I revisit Co-Diagnostics. I later revisited it in "Co-Diagnostics: A+ Student Faces New Tests". I first encountered Co-Diagnostics ( NASDAQ: CODX) when researching my 12/2020 article "A+ Top Quant Rated Healthcare Stocks For Value, Growth, And Profitability". ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |